Uterine Fibroids Clinical Trial
— FAST-EUOfficial title:
Symptom Effectiveness Study of VizAblateā¢ Intrauterine Ultrasound-Guided RF Ablation (IUUSgRFA) in the Ablation of Uterine Fibroids
The primary objective of this study is to establish the effectiveness and confirm the safety of the VizAblate System in ablating symptomatic uterine fibroids.
Status | Terminated |
Enrollment | 51 |
Est. completion date | March 2014 |
Est. primary completion date | March 2014 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 28 Years and older |
Eligibility |
Inclusion Criteria: - 28 years of age or older - Regular, consistent menstrual cycles - History of excessive bleeding - One Menstrual Pictogram score = 120 during a one-month screening period - Baseline Uterine Fibroid Symptom & Quality of Life (UFS-QOL) Symptom Severity Subscale (SSS) score = 20 - Between 1 and 5 Target Fibroids between 1 cm and 5 cm and/or maximum volume 82.4cc - At least one fibroid must indent the endometrium - Subject is not at material risk for pregnancy. - Subject is willing to maintain use or non-use of hormonal contraception - Subject is willing to have uniform maintenance (use or non-use) of any antifibrinolytic or nonsteroidal anti-inflammatory agents Exclusion Criteria: - Subserosal fibroids with bulk symptoms - Presence of type 0 intracavitary fibroids - Any Target Fibroid > 5 cm in maximum diameter with a volume > 82.4cc - Any fibroid that obstructs access of the VizAblate probe - Postmenopausal by history - Desire for current or future fertility - Hemoglobin < 6 g/dl - Pregnancy - Evidence of disorders of hemostasis - Use of Gonadotropin-releasing hormone (GnRH) agonist or implantable or injectable progestin and/or estrogen, Selective Estrogen Receptor Modulators (SERM) or selective progesterone receptor modulator (SPRM) - Short-term use of hormonal medication for management of bleeding - Evidence for current cervical dysplasia - Endometrial hyperplasia - Confirmed abdominal / pelvic malignancy within the previous five years - Active pelvic infection - Clinically significant adenomyosis - Previous uterine artery embolization. Previous surgical or ablative treatment for fibroids or menorrhagia within previous 12 months - Current use of anticoagulant therapy - Need for emergency surgery to treat fibroid symptoms - Concomitant intrauterine polyps > 1.0 cm - Contraindication to MRI - Renal insufficiency - Uncontrolled hypertension lasting 2 years or more - One or more treatable fibroids that are calcified - Chronic pelvic pain - Presence of an extrauterine pelvic mass - Presence of a tubal implant for sterilization - Previous pelvic irradiation - Endometrial cavity length < 4.5 cm |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Mexico | Universidad Autonoma de Nuevo Leon (UANL) | Monterrey | Nuevo Leon |
Netherlands | Vrije Universiteit Medisch Centrum | Amsterdam | North Holland |
Netherlands | Medisch Spectrum Twente | Enschede | |
Netherlands | St. Antonius Ziekenhuis | Nieuwegein | Utrecht |
Netherlands | Máxima Medisch Centrum | Veldhoven | Noord-Brabant |
United Kingdom | Birmingham Women's NHS Foundation Trust | Birmingham | West Midlands |
United Kingdom | Bradford Teaching Hospitals NHS Trust | Bradford | West Yorkshire |
United Kingdom | Princess Royal Hospital | Haywards Health | West Sussex |
United Kingdom | University College Hospital | London | |
United Kingdom | Royal London Hospital | Whitechapel | London |
Lead Sponsor | Collaborator |
---|---|
Gynesonics |
Mexico, Netherlands, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Subject satisfaction | 3 month, 6 month, 12 months | No | |
Other | Anesthesia regimen | Day of procedure | No | |
Other | System ease of use | End of study | No | |
Other | Subject pain and tolerance of procedure | Day of procedure | No | |
Other | HRQL sub scale of Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaire | 3 month, 6 month, 12 months | No | |
Other | EuroQOL EQ-5D | 3 month, 6 month, 12 month | No | |
Other | Length of Stay | Day of procedure | No | |
Other | Nonsurgical reintervention for menorrhagia | 30 day, 3 month, 6 month, 12 month | No | |
Primary | Mean percentage change in target fibroid perfused volume | 3 months | No | |
Secondary | Number of adverse events | Procedure safety will be assessed by recording all adverse events that occur on the day of the procedure. Longer-term safety will be assessed by recording at each follow-up visit any untoward medical occurrence since baseline. Each adverse event will be assessed for severity and relationship to study device. | procedure through 12 mo | Yes |
Secondary | Percentage reduction in Menstrual Pictogram score | baseline through 12 months | No | |
Secondary | Percentage reduction in the Symptom Severity Subscale (SSS) of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire | baseline through 12 months | No | |
Secondary | Rate of surgical reintervention for menorrhagia | through 12 months | No | |
Secondary | Return to normal daily activity | 2 weeks or until returned to normal activity | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01441635 -
Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids
|
Phase 2 | |
Completed |
NCT00958334 -
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
|
Phase 2 | |
Withdrawn |
NCT04567589 -
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in Canada
|
||
Recruiting |
NCT05078307 -
Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids
|
N/A | |
Recruiting |
NCT02283502 -
Clinical Test of the MRgHIFU System on Uterine Fibroids
|
Phase 1 | |
Completed |
NCT01631903 -
Extension of Study ZPV-200
|
Phase 2 | |
Completed |
NCT01739621 -
Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200
|
Phase 2 | |
Withdrawn |
NCT00768742 -
Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study
|
N/A | |
Completed |
NCT00152256 -
A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids
|
Phase 3 | |
Not yet recruiting |
NCT03586947 -
Association Between Vitamin D and the Risk of Uterine Fibroids
|
N/A | |
Completed |
NCT02925494 -
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
|
Phase 3 | |
Not yet recruiting |
NCT06055114 -
Study on Vaginal Microecology and Cervical Local Immune Function in Patients With Uterine Fibroids of Childbearing Age
|
||
Terminated |
NCT05026502 -
A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
|
||
Withdrawn |
NCT04567095 -
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada
|
||
Withdrawn |
NCT03699176 -
Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
|
Phase 3 | |
Not yet recruiting |
NCT02884960 -
Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization
|
N/A | |
Completed |
NCT02472184 -
Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy
|
N/A | |
Completed |
NCT01452659 -
Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids
|
Phase 2 | |
Terminated |
NCT01555073 -
Preemptive Analgesia Following Uterine Artery Embolization
|
Phase 4 | |
Completed |
NCT01229826 -
Magnetic Resonance Elastography (MRE) of Uterine Fibroids
|
N/A |